EatMoreFruit, a UK top 10 independent healthcare communication agency, today announced the launch of its European Network to ...

Around 86% of clinical trials do not meet patient recruitment goals, ultimately failing to improve patient outcomes and ...

Novartis’ Scemblix (asciminib) has been granted accelerated approval by the US Food and Drug Administration (FDA) to treat a new subset of chronic myeloid leukaemia (CML) patients. The STAMP inhibitor ...

Dermavant Sciences has shared positive long-term results for its plaque psoriasis-approved Vtama (tapinarof) cream in adults and children as young as two years old with atopic dermatitis (AD).

Launches have the power to significantly shape an organisation’s trajectory, and ensuring their success is critical for long-term growth. Knowing this, it amazes me how many pharmaceutical ...

This blog will discuss some important aspects to consider to maximise patient retention on your flu clinical trials. For more information on patient recruitment considerations, check out our previous ...

Generative AI platforms are revolutionizing drug discovery, driving significant biopharma dealmaking by enabling the design of innovative small-molecule and biologic drug candidates. The launch of ...

AbbVie has announced that it will be acquiring Aliada Therapeutics for $1.4bn, marking a notable boost to its neuroscience pipeline. The deal gives AbbVie access to Aliada’s therapies that use a novel ...

Johnson & Johnson (J&J) has shared positive results from a late-stage study of its dual-acting IL-23 inhibitor Tremfya (guselkumab) in plaque psoriasis patients. The phase 3b SPECTREM trial has been ...

Major players from across the UK’s health and life sciences sector have responded to the Autumn Budget delivered by Labour Chancellor Rachel Reeves. The Budget is Labour’s first in 14 years and ...

After the recent Paralympics, I can’t help but be in awe of the individuals who participated and achieved such amazing feats, despite having everyday challenges most of us can hardly comprehend. It is ...